COVID-19 resources & COVID-19 vaccine information

Sword Assay for Human IL-23

Interleukin-23 (IL-23) is a pro-inflammatory cytokine composed of two subunits, p19 and p401. Its p40 subunit is also shared with IL-12. However, IL-23 and IL-12 activate distinct cellular pathways.2 IL-23 induces the differentiation of Th17 cells from naïve CD4+ helper T cells to produce IL-17A, IL-17F, IL-6, IL-22, TNFα and GM-CSF. IL-23 also induces tissue macrophages to produce IL-1, TNFα and IL-23.

IL-23 is secreted by both macrophages and dendritic cells as a host defense and wound healing response. It has been implicated in several inflammatory and autoimmune diseases, including psoriasis, psoriatic arthritis, Crohn’s Disease and ankylosing spondylitis. Genome-wide association studies (GWAS) have also linked IL-23 to ulcerative colitis, inflammatory bowel disease (IBD) and graft-versus-host disease.2

This Sword Assay has been optimized for use with the R&D Systems Quantikine ELISA for Human IL-23 (Catalog No. D2300B).

Assay Type:

Sandwich ELISA

Product #:


See the Sword Performance Difference


  1. Duvallet E, et al.: Interleukin-23: a key cytokine in inflammatory diseases. Ann Med 2011, 43(7):503-11.
  2. Teng MWL, et al.: IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nature Medicine 2015, 21:719-729.

Ready to Optimize Your Assay?

Put Sword to the test. Give us 6 days and we’ll show you just how much we can boost your specific assay’s sensitivity, precision, and accuracy. We’ll even assess your first target assay free of charge.

Purchase this Assay

Contact the Sword team today to discuss how best to implement our Human IL-23 assay for your needs.


Learn more about Sword’s patented technology and how it can be optimally configured for your specific matrix needs.